Browse Arkansas Code titles and sections
21 U.S.C. § 822 — Persons required to register
Federal law — U.S. Code and appendices · legal_authorities
**(a) Period of registration**
(1) Every person who manufactures or distributes any controlled substance or list I chemical, or who proposes to engage in the manufacture or distribution of any controlled substance or list I chemical, shall obtain annually a registration issued by the Attorney General in accordance with the rules and regulations promulgated by him.
(2) Every person who dispenses, or who proposes to dispense, any controlled substance, shall obtain from the Attorney General a registration issued in accordance with the rules and regulations promulgated by him. The Attorney General shall, by regulation, determine the period of such registrations. In no event, however, shall such registrations be issued for less than one year nor for more than three years.
(3)
(A) Except as provided in subparagraph (C), the registration of any registrant under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals terminates if and when such registrant—
(i) dies;
(ii) ceases legal existence;
(iii) discontinues business or professional practice; or
(iv) surrenders such registration.
(B) In the case of such a registrant who ceases legal existence or discontinues business or professional practice, such registrant shall promptly notify the Attorney General in writing of such fact.
(C) No registration under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals, and no authority conferred thereby, may be assigned or otherwise transferred except upon such conditions as the Attorney General may specify and then only pursuant to written consent. A registrant to whom a registration is assigned or transferred pursuant to the preceding sentence may not manufacture, distr
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 822
Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: 9204d3149a24e343de5aca8a8165e8181b666effc5b34e1d13f39384fe36c02f. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:record_usc_04adc167d79c47674c48b796
Source file: Laws/federal/codes/united-states-code/title-21/section-822-persons-required-to-register--7e34d3cabd.md
Pages: Not recorded – Not recorded
Passage SHA-256: 5c42091cbe9d384246dc6fdf823da42776de079b01dff6c1aa3ccd586651635d
Source location: Title 21, Chapter 13, § 822; chapter-013-drug-abuse-prevention-and-control.md
Stored source content
**(a) Period of registration**
(1) Every person who manufactures or distributes any controlled substance or list I chemical, or who proposes to engage in the manufacture or distribution of any controlled substance or list I chemical, shall obtain annually a registration issued by the Attorney General in accordance with the rules and regulations promulgated by him.
(2) Every person who dispenses, or who proposes to dispense, any controlled substance, shall obtain from the Attorney General a registration issued in accordance with the rules and regulations promulgated by him. The Attorney General shall, by regulation, determine the period of such registrations. In no event, however, shall such registrations be issued for less than one year nor for more than three years.
(3)
(A) Except as provided in subparagraph (C), the registration of any registrant under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals terminates if and when such registrant—
(i) dies;
(ii) ceases legal existence;
(iii) discontinues business or professional practice; or
(iv) surrenders such registration.
(B) In the case of such a registrant who ceases legal existence or discontinues business or professional practice, such registrant shall promptly notify the Attorney General in writing of such fact.
(C) No registration under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals, and no authority conferred thereby, may be assigned or otherwise transferred except upon such conditions as the Attorney General may specify and then only pursuant to written consent. A registrant to whom a registration is assigned or transferred pursuant to the preceding sentence may not manufacture, distribute, or dispense controlled substances or list I chemicals pursuant to such registration until the Attorney General receives such written consent.
(D) In the case of a registrant under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals desiring to discontinue business or professional practice altogether or with respect to controlled substances and list I chemicals (without assigning or transferring such business or professional practice to another entity), such registrant shall return to the Attorney General for cancellation—
(i) the registrant’s certificate of registration;
(ii) any unexecuted order forms in the registrant’s possession; and
(iii) any other documentation that the Attorney General may require.
**(b) Authorized activities** Persons registered by the Attorney General under this subchapter to manufacture, distribute, or dispense controlled substances or list I chemicals are authorized to possess, manufacture, distribute, or dispense such substances or chemicals (including any such activity in the conduct of research) to the extent authorized by their registration and in conformity with the other provisions of this subchapter.
**(c) Exceptions** The following persons shall not be required to register and may lawfully possess any controlled substance or list I chemical under this subchapter:
(1) An agent or employee of any registered manufacturer, distributor, or dispenser of any controlled substance or list I chemical if such agent or employee is acting in the usual course of his business or employment.
(2) A common or contract carrier or warehouseman, or an employee thereof, whose possession of the controlled substance or list I chemical is in the usual course of his business or employment.
(3) An ultimate user who possesses such substance for a purpose specified in [section 802(27) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802/27&num=0&edition=prelim).
(4) An agent or employee of a research institution that is conducting research with a controlled substance if—
(A) the agent or employee is acting within the scope of the professional practice of the agent or employee;
(B) another agent or employee of the institution is registered to conduct research with a controlled substance in the same schedule;
(C) the researcher who is so registered—
(i) informs the Attorney General of the name, position title, and employing institution of the agent or employee who is not separately registered;
(ii) authorizes that agent or employee to perform research under the registration of the registered researcher; and
(iii) affirms that any act taken by that agent or employee involving a controlled substance shall be attributable to the registered researcher, as if the researcher had directly committed the act, for purposes of any proceeding under [section 824(a) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section824/a&num=0&edition=prelim) to suspend or revoke the registration of the registered researcher; and
(D) the Attorney General does not, within 30 days of receiving the information, authorization, and affirmation described in subparagraph (C), refuse, for a reason listed in [section 824(a) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section824/a&num=0&edition=prelim), to allow the agent or employee to possess the substance without a separate registration.
**(d) Waiver** The Attorney General may, by regulation, waive the requirement for registration of certain manufacturers, distributors, or dispensers if he finds it consistent with the public health and safety.
**(e) Separate registration**
(1) A separate registration shall be required at each principal place of business or professional practice where the applicant manufactures, distributes, or dispenses controlled substances or list I chemicals.
(2) Notwithstanding paragraph (1), a registrant who is a veterinarian shall not be required to have a separate registration in order to transport and dispense controlled substances in the usual course of veterinary practice at a site other than the registrant’s registered principal place of business or professional practice, so long as the site of transporting and dispensing is located in a State where the veterinarian is licensed to practice veterinary medicine and is not a principal place of business or professional practice.
(3) Notwithstanding paragraph (1), a registrant that is dispensing pursuant to [section 823(h) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/h&num=0&edition=prelim) narcotic drugs to individuals for maintenance treatment or detoxification treatment shall not be required to have a separate registration to incorporate one or more mobile medication units into the registrant’s practice to dispense such narcotics at locations other than the registrant’s principal place of business or professional practice described in paragraph (1), so long as the registrant meets such standards for operation of a mobile medication unit as the Attorney General may establish.
(4)
(A) Notwithstanding paragraph (1), a person registered to conduct research with a controlled substance under [section 823(g) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/g&num=0&edition=prelim) may conduct the research under a single registration if—
(i) the research occurs exclusively on sites all of which are—
(I) within the same city or county; and
(II) under the control of the same institution, organization, or agency; and
(ii) before commencing the research, the researcher notifies the Attorney General of each site where—
(I) the research will be conducted; or
(II) the controlled substance will be stored or administered.
(B) A site described in subparagraph (A) shall be included in a registration described in that subparagraph only if the researcher has notified the Attorney General of the site—
(i) in the application for the registration; or
(ii) before the research is conducted, or before the controlled substance is stored or administered, at the site.
(C) The Attorney General may, in consultation with the Secretary, issue regulations addressing, with respect to research sites described in subparagraph (A)—
(i) the manner in which controlled substances may be delivered to the research sites;
(ii) the storage and security of controlled substances at the research sites;
(iii) the maintenance of records for the research sites; and
(iv) any other matters necessary to ensure effective controls against diversion at the research sites.
**(f) Inspection**
(1) The Attorney General is authorized to inspect the establishment of a registrant or applicant for registration in accordance with the rules and regulations promulgated by him.
(2)
(A) If a person is registered to conduct research with a controlled substance and applies for a registration, or for a modification of a registration, to conduct research with a second controlled substance that is in the same schedule as the first controlled substance, or is in a schedule with a higher numerical designation than the schedule of the first controlled substance, a new inspection by the Attorney General of the registered location is not required.
(B) Nothing in subparagraph (A) shall prohibit the Attorney General from conducting an inspection that the Attorney General determines necessary to ensure that a registrant maintains effective controls against diversion.
**(g) Delivery of controlled substances by ultimate users for disposal**
(1) An ultimate user who has lawfully obtained a controlled substance in accordance with this subchapter may, without being registered, deliver the controlled substance to another person for the purpose of disposal of the controlled substance if—
(A) the person receiving the controlled substance is authorized under this subchapter to engage in such activity; and
(B) the disposal takes place in accordance with regulations issued by the Attorney General to prevent diversion of controlled substances.
(2) In developing regulations under this subsection, the Attorney General shall take into consideration the public health and safety, as well as the ease and cost of program implementation and participation by various communities. Such regulations may not require any entity to establish or operate a delivery or disposal program.
(3) The Attorney General may, by regulation, authorize long-term care facilities, as defined by the Attorney General by regulation, to dispose of controlled substances on behalf of ultimate users who reside, or have resided, at such long-term care facilities in a manner that the Attorney General determines will provide effective controls against diversion and be consistent with the public health and safety.
(4) If a person dies while lawfully in possession of a controlled substance for personal use, any person lawfully entitled to dispose of the decedent’s property may deliver the controlled substance to another person for the purpose of disposal under the same conditions as provided in paragraph (1) for an ultimate user.
(5)
(A) In the case of a person receiving hospice care, an employee of a qualified hospice program, acting within the scope of employment, may handle, without being registered under this section, any controlled substance that was lawfully dispensed to the person receiving hospice care, for the purpose of disposal of the controlled substance so long as such disposal occurs onsite in accordance with all applicable Federal, State, Tribal, and local law and—
(i) the disposal occurs after the death of a person receiving hospice care;
(ii) the controlled substance is expired; or
(iii)
(I) the employee is—
(aa) the physician of the person receiving hospice care; and
(bb) registered under [section 823(g) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/g&num=0&edition=prelim); and
(II) the hospice patient no longer requires the controlled substance because the plan of care of the hospice patient has been modified.
(B) For the purposes of this paragraph:
(i) The terms “hospice care” and “hospice program” have the meanings given to those terms in [section 1395x(dd) of title 42](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395x/dd&num=0&edition=prelim).
(ii) The term “employee of a qualified hospice program” means a physician, physician assistant, nurse, or other person who—
(I) is employed by, or pursuant to arrangements made by, a qualified hospice program;
(II)
(aa) is licensed to perform medical or nursing services by the jurisdiction in which the person receiving hospice care was located; and
(bb) is acting within the scope of such employment in accordance with applicable State law; and
(III) has completed training through the qualified hospice program regarding the disposal of controlled substances in a secure and responsible manner so as to discourage abuse, misuse, or diversion.
(iii) The term “qualified hospice program” means a hospice program that—
(I) has written policies and procedures for assisting in the disposal of the controlled substances of a person receiving hospice care after the person’s death;
(II) at the time when the controlled substances are first ordered—
(aa) provides a copy of the written policies and procedures to the patient or patient representative and family;
(bb) discusses the policies and procedures with the patient or representative and the family in a language and manner that they understand to ensure that these parties are educated regarding the safe disposal of controlled substances; and
(cc) documents in the patient’s clinical record that the written policies and procedures were provided and discussed; and
(III) at the time following the disposal of the controlled substances—
(aa) documents in the patient’s clinical record the type of controlled substance, dosage, route of administration, and quantity so disposed; and
(bb) the time, date, and manner in which that disposal occurred.
**(h) Continuation of research on substances newly added to schedule I** If a person is conducting research on a substance when the substance is added to schedule I, and the person is already registered to conduct research with a controlled substance in schedule I—
(1) not later than 90 days after the scheduling of the newly scheduled substance, the person shall submit a completed application for registration or modification of existing registration, to conduct research on the substance, in accordance with regulations issued by the Attorney General for purposes of this paragraph;
(2) the person may, notwithstanding subsections (a) and (b), continue to conduct the research on the substance until—
(A) the person withdraws the application described in paragraph (1) of this subsection; or
(B) the Attorney General serves on the person an order to show cause proposing the denial of the application under [section 824(c) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section824/c&num=0&edition=prelim);
(3) if the Attorney General serves an order to show cause as described in paragraph (2)(B) and the person requests a hearing, the hearing shall be held on an expedited basis and not later than 45 days after the request is made, except that the hearing may be held at a later time if so requested by the person; and
(4) if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.
**(i) Treatment of certain manufacturing activities as coincident to research**
(1) **In general** — Except as provided in paragraph (3), a person who is registered to perform research on a controlled substance may perform manufacturing activities with small quantities of that substance, including activities described in paragraph (2), without being required to obtain a manufacturing registration, if—
(A) the activities are performed for the purpose of the research; and
(B) the activities and the quantities of the substance involved in the activities are stated in—
(i) a notification submitted to the Attorney General under [section 823(n) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/n&num=0&edition=prelim);
(ii) a research protocol filed with an application for registration approval under [section 823(g) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/g&num=0&edition=prelim); or
(iii) a notification to the Attorney General that includes—
(I) the name of the registrant; and
(II) an attestation that the research to be conducted with the small quantities of manufactured substance is consistent with the scope of the research that is the basis for the registration.
(2) **Activities included** — Activities permitted under paragraph (1) include—
(A) processing the substance to create extracts, tinctures, oils, solutions, derivatives, or other forms of the substance consistent with—
(i) the information provided as part of a notification submitted to the Attorney General under [section 823(n) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/n&num=0&edition=prelim); or
(ii) a research protocol filed with an application for registration approval under [section 823(g) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/g&num=0&edition=prelim); and
(B) dosage form development studies performed for the purpose of requesting an investigational new drug exemption under [section 355(i) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355/i&num=0&edition=prelim).
(3) **Exception regarding marihuana** — The authority under paragraph (1) to manufacture substances does not include the authority to grow marihuana.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
The Congress makes the following findings and declarations:
(1) Many of the drugs included within this subchapter have a useful and legitimate medical purpose and are necessary to maintain the health and general welfare of the American people.
(2) The illegal importation, manufacture, distribution, and possession and improper use of controlled substances have a substantial and detrimental effect on the health and general welfare of the American people.
(3) A major portion of the traffic in controlled substances flows through interstate and foreign commerce. Incidents of the traffic which are not an integral part of the interstate or foreign flow, such as manufacture, local distribution, and possession, nonetheless have a substantial and direct effect upon interstate commerce because—
(A) after manufacture, many controlled substances are transported in interstate commerce,
(B) controlled substances distributed locally usually have been transported in interstate commerce immediately before their distribution, and
(C) controlled substances possessed commonly flow through interstate commerce immediately prior to such possession.
(4) Local distribution and possession of controlled substances contribute to swelling the interstate traffic in such substances.
(5) Controlled substances manufactured and distributed intrastate cannot be differentiated from controlled substances manufactured and distributed interstate. Thus, it is not feasible to distinguish, in terms of controls, between controlled substances manufactured and distributed interstate and controlled substances manufactured and distributed intrastate.
(6) Federal control of the intrastate incidents of the traffic in controlled substances is essential to the effective control of the interstate incidents
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 801
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Grounds** A registration pursuant to [section 823 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823&num=0&edition=prelim) to manufacture, distribute, or dispense a controlled substance or a list I chemical may be suspended or revoked by the Attorney General upon a finding that the registrant—
(1) has materially falsified any application filed pursuant to or required by this subchapter or subchapter II;
(2) has been convicted of a felony under this subchapter or subchapter II or any other law of the United States, or of any State, relating to any substance defined in this subchapter as a controlled substance or a list I chemical;
(3) has had his State license or registration suspended, revoked, or denied by competent State authority and is no longer authorized by State law to engage in the manufacturing, distribution, or dispensing of controlled substances or list I chemicals or has had the suspension, revocation, or denial of his registration recommended by competent State authority;
(4) has committed such acts as would render his registration under [section 823 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823&num=0&edition=prelim) inconsistent with the public interest as determined under such section; or
(5) has been excluded (or directed to be excluded) from participation in a program pursuant to [section 1320a–7(a) of title 42](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320a–7/a&num=0&edition=prelim).
A registration pursuant to [section 823(h) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section823/h&num=0&edition=prelim) to dispense a narcotic drug for maintenance treatment or detoxification tr
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 824
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Manufacturers of controlled substances in schedule I or II** The Attorney General shall register an applicant to manufacture controlled substances in schedule I or II if he determines that such registration is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. In determining the public interest, the following factors shall be considered:
(1) maintenance of effective controls against diversion of particular controlled substances and any controlled substance in schedule I or II compounded therefrom into other than legitimate medical, scientific, research, or industrial channels, by limiting the importation and bulk manufacture of such controlled substances to a number of establishments which can produce an adequate and uninterrupted supply of these substances under adequately competitive conditions for legitimate medical, scientific, research, and industrial purposes;
(2) compliance with applicable State and local law;
(3) promotion of technical advances in the art of manufacturing these substances and the development of new substances;
(4) prior conviction record of applicant under Federal and State laws relating to the manufacture, distribution, or dispensing of such substances;
(5) past experience in the manufacture of controlled substances, and the existence in the establishment of effective control against diversion; and
(6) such other factors as may be relevant to and consistent with the public health and safety.
**(b) Distributors of controlled substances in schedule I or II** The Attorney General shall register an applicant to distribute a controlled substance in schedule I or II unless he determines that the issuance of such registration is inconsist
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 823
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Definitions** As used in this section—
(1) the term “manufacture, preparation, propagation, compounding, or processing” shall include repackaging or otherwise changing the container, wrapper, or labeling of any drug package or device package in furtherance of the distribution of the drug or device from the original place of manufacture to the person who makes final delivery or sale to the ultimate consumer or user; and
(2) the term “name” shall include in the case of a partnership the name of each partner and, in the case of a corporation, the name of each corporate officer and director, and the State of incorporation.
**(b) Annual registration**
(1) During the period beginning on October 1 and ending on December 31 of each year, every person who owns or operates any establishment in any State engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or drugs shall register with the Secretary the name of such person, places of business of such person, all such establishments, the unique facility identifier of each such establishment, and a point of contact e-mail address.
(2) During the period beginning on October 1 and ending on December 31 of each year, every person who owns or operates any establishment in any State engaged in the manufacture, preparation, propagation, compounding, or processing of a device or devices shall register with the Secretary his name, places of business, and all such establishments.
(3) The Secretary shall specify the unique facility identifier system that shall be used by registrants under paragraph (1). The requirement to include a unique facility identifier in a registration under paragraph (1) shall not apply until the date that the identifier system is specified by the Secretary under the pr
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 360
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
As used in this subchapter:
(1) The term “addict” means any individual who habitually uses any narcotic drug so as to endanger the public morals, health, safety, or welfare, or who is so far addicted to the use of narcotic drugs as to have lost the power of self-control with reference to his addiction.
(2) The term “administer” refers to the direct application of a controlled substance to the body of a patient or research subject by—
(A) a practitioner (or, in his presence, by his authorized agent), or
(B) the patient or research subject at the direction and in the presence of the practitioner,
whether such application be by injection, inhalation, ingestion, or any other means.
(3) The term “agent” means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser; except that such term does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman, when acting in the usual and lawful course of the carrier’s or warehouseman’s business.
(4) The term “Drug Enforcement Administration” means the Drug Enforcement Administration in the Department of Justice.
(5) The term “control” means to add a drug or other substance, or immediate precursor, to a schedule under part B of this subchapter, whether by transfer from another schedule or otherwise.
(6) The term “controlled substance” means a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. The term does not include distilled spirits, wine, malt beverages, or tobacco, as those terms are defined or used in subtitle E of the Internal Revenue Code of 1986.
(7) The term “counterfeit substance” means a controlled substance which, or the container or labelin
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 802
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a)** Whoever takes or attempts to take from the person or presence of another by force or violence or by intimidation any material or compound containing any quantity of a controlled substance belonging to or in the care, custody, control, or possession of a person registered with the Drug Enforcement Administration under section 302 of the Controlled Substances Act ([21 U.S.C. 822](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section822&num=0&edition=prelim)) shall, except as provided in subsection (c), be fined under this title or imprisoned not more than twenty years, or both, if (1) the replacement cost of the material or compound to the registrant was not less than $500, (2) the person who engaged in such taking or attempted such taking traveled in interstate or foreign commerce or used any facility in interstate or foreign commerce to facilitate such taking or attempt, or (3) another person was killed or suffered significant bodily injury as a result of such taking or attempt.
**(b)** Whoever, without authority, enters or attempts to enter, or remains in, the business premises or property of a person registered with the Drug Enforcement Administration under section 302 of the Controlled Substances Act ([21 U.S.C. 822](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section822&num=0&edition=prelim)) with the intent to steal any material or compound containing any quantity of a controlled substance shall, except as provided in subsection (c), be fined under this title or imprisoned not more than twenty years, or both, if (1) the replacement cost of the controlled substance to the registrant was not less than $500, (2) the person who engaged in such entry or attempted such entry or who remained in such premises or prop
Source: Supplied U.S. Code snapshot — release unconfirmed · 18 U.S.C. § 2118
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a)** For purposes of this subchapter—
(1) The term “import” means, with respect to any article, any bringing in or introduction of such article into any area (whether or not such bringing in or introduction constitutes an importation within the meaning of the tariff laws of the United States).
(2) The term “customs territory of the United States” has the meaning assigned to such term by general note 2 of the Harmonized Tariff Schedule of the United States.
**(b)** Each term defined in [section 802 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802&num=0&edition=prelim) shall have the same meaning for purposes of this subchapter as such term has for purposes of subchapter I.
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 951
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Compliance With Credentialing Requirements.—** The Secretary shall ensure that each medical center of the Department, in a consistent manner—
(1) compiles, verifies, and reviews documentation for each health care professional of the Department at such medical center regarding, at a minimum—
(A) the professional licensure, certification, or registration of the health care professional;
(B) whether the health care professional holds a Drug Enforcement Administration registration; and
(C) the education, training, experience, malpractice history, and clinical competence of the health care professional; and
(2) continuously monitors any changes to the matters under paragraph (1), including with respect to suspensions, restrictions, limitations, probations, denials, revocations, and other changes, relating to the failure of a health care professional to meet generally accepted standards of clinical practice in a manner that presents reasonable concern for the safety of patients.
**(b) Registration Regarding Controlled Substances.—**
(1) Except as provided in paragraph (2), the Secretary shall ensure that each covered health care professional holds an active Drug Enforcement Administration registration.
(2) The Secretary shall—
(A) determine the circumstances in which a medical center of the Department must obtain a waiver under section 302(d) of the Controlled Substances Act ([21 U.S.C. 822(d)](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section822/d&num=0&edition=prelim)) with respect to covered health care professionals; and
(B) establish a process for medical centers to request such waivers.
(3) In carrying out paragraph (1), the Secretary shall ensure that each medical center of the Department monitors the Drug Enforceme
Source: Supplied U.S. Code snapshot — release unconfirmed · 38 U.S.C. § 7414
Stored review status: release_metadata_unconfirmed. Incoming connection: Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
Page 805
TITLE 21—FOOD AND DRUGS
§ 822
(D) any actions taken by the manufacturer
to prevent diversion of the drug product; and
(E) such other factors as are relevant to
and consistent with the public health and
safety, including the factors described in
subsection (b) as applied to the drug prod-
uct.
(3) Status pending application for reinstate-
ment
A transaction involving a particular drug
product that is the subject of a bona fide pend-
ing application for reinstatement of exemp-
tion filed with the Attorney General not later
than 60 days after a regulation removing the
exemption is issued pursuant to subsection (a)
shall not be considered to be a regulated
transaction if the transaction occurs during
the pendency of the application and, if the At-
torney General denies the application, during
the period of 60 days following the date on
which the Attorney General denies the appli-
cation, unless—
(A) the Attorney General has evidence
that, applying the factors described in sub-
section (b) to the drug product, the drug
product is being diverted; and
(B) the Attorney General so notifies the
applicant.
(4) Amendment and modification
A regulation reinstating an exemption under
paragraph (1) may be modified or revoked with
respect to a particular drug product upon a
finding that—
(A) applying the factors described in sub-
section (b) to the drug product, the drug
product is being diverted; or
(B) there is a significant change in the
data that led to the issuance of the regula-
tion.
(Pub. L. 91–513, title II, § 204, as added Pub. L.
103–200, § 2(b)(1), Dec. 17, 1993, 107 Stat. 2334;
amended Pub. L. 104–237, title IV, § 401(c), Oct. 3,
1996, 110 Stat. 3108; Pub. L. 109–177, title VII,
§ 712(a)(2), Mar. 9, 2006, 120 Stat. 263.)
Editorial No
Source: Supplied 2024 U.S. Code historical extraction · 21 U.S.C. § 822
Stored review status: historical_2024_not_currentness_verified. Same stored citation; legal effect and authority still require review.